CN109152735B - 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法 - Google Patents

包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法 Download PDF

Info

Publication number
CN109152735B
CN109152735B CN201780026989.5A CN201780026989A CN109152735B CN 109152735 B CN109152735 B CN 109152735B CN 201780026989 A CN201780026989 A CN 201780026989A CN 109152735 B CN109152735 B CN 109152735B
Authority
CN
China
Prior art keywords
inflammatory
lipid
roflumide
lipid nanoparticle
lipophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780026989.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109152735A (zh
Inventor
L.林福斯
T.凯尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN109152735A publication Critical patent/CN109152735A/zh
Application granted granted Critical
Publication of CN109152735B publication Critical patent/CN109152735B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780026989.5A 2016-05-09 2017-05-08 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法 Active CN109152735B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662333574P 2016-05-09 2016-05-09
US62/333574 2016-05-09
US201662359429P 2016-07-07 2016-07-07
US62/359429 2016-07-07
US201762449623P 2017-01-24 2017-01-24
US62/449623 2017-01-24
PCT/EP2017/060891 WO2017194454A1 (en) 2016-05-09 2017-05-08 Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof

Publications (2)

Publication Number Publication Date
CN109152735A CN109152735A (zh) 2019-01-04
CN109152735B true CN109152735B (zh) 2022-03-11

Family

ID=58671696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780026989.5A Active CN109152735B (zh) 2016-05-09 2017-05-08 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法

Country Status (6)

Country Link
US (2) US11458106B2 (enExample)
EP (1) EP3454835B1 (enExample)
JP (2) JP7066632B2 (enExample)
CN (1) CN109152735B (enExample)
ES (1) ES2871537T3 (enExample)
WO (1) WO2017194454A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
AU2016285852B2 (en) 2015-06-29 2020-12-17 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
LT3368507T (lt) 2015-10-28 2023-03-10 Acuitas Therapeutics Inc. Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui
ES2871537T3 (es) 2016-05-09 2021-10-29 Astrazeneca Ab Nanopartículas lipídicas que comprenden agentes antiinflamatorios lipófilos y métodos de uso de las mismas
EP3532103B1 (en) * 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CA3061612A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CA3073018A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
WO2020146805A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
JP2022532075A (ja) * 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａを送達するために脂質ナノ粒子を使用する方法、及びこの脂質ナノ粒子を含む医薬組成物
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
IL294624A (en) * 2020-01-21 2022-09-01 Etherna Immunotherapies Nv lipid nanoparticles
BR112023000327A2 (pt) 2020-07-16 2023-01-31 Acuitas Therapeutics Inc Lipídeos catiônicos para o uso em nanopartículas lipídicas
WO2023080753A1 (ko) * 2021-11-05 2023-05-11 주식회사 지투지바이오 비경구 병용투여용 약학적 키트
KR20240123832A (ko) 2021-12-16 2024-08-14 아퀴타스 테라퓨틱스 인크. 지질 나노입자 제형에 사용하기 위한 지질
EP4436558B1 (de) * 2022-02-02 2025-09-24 MSLsolutions GmbH Verfahren zur medikament- und impfstoffherstellung
CN114617980A (zh) * 2022-03-09 2022-06-14 广州国家实验室 可电离脂质纳米颗粒及其应用
AU2024207086A1 (en) * 2023-01-09 2025-07-24 Northmirs, Inc. Microrna-based particle for the treatment of dysregulated immune response
WO2025215636A1 (en) 2024-04-08 2025-10-16 Yeda Research And Development Co. Ltd. Anti-defense system polypeptides and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1171047A (zh) * 1994-12-22 1998-01-21 阿斯特拉公司 用于吸入法的原脂质体粉末
WO2006031471A2 (en) * 2004-09-01 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Liposomal vectors
CN104873464A (zh) * 2009-06-10 2015-09-02 阿尔尼拉姆医药品有限公司 改进的脂质制剂
CN105283175A (zh) * 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101708338B (zh) * 2008-12-26 2014-06-04 中国人民解放军军事医学科学院放射与辐射医学研究所 含甾体结构的前药及其高度分散制剂
EA201270019A1 (ru) * 2009-06-15 2012-06-29 Элнилэм Фармасьютикалз, Инк. Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
EP2688560A2 (en) 2011-03-24 2014-01-29 Leo Pharma A/S A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
DE12858350T1 (de) * 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
ES2871537T3 (es) 2016-05-09 2021-10-29 Astrazeneca Ab Nanopartículas lipídicas que comprenden agentes antiinflamatorios lipófilos y métodos de uso de las mismas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1171047A (zh) * 1994-12-22 1998-01-21 阿斯特拉公司 用于吸入法的原脂质体粉末
WO2006031471A2 (en) * 2004-09-01 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Liposomal vectors
CN104873464A (zh) * 2009-06-10 2015-09-02 阿尔尼拉姆医药品有限公司 改进的脂质制剂
CN105283175A (zh) * 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
CN105338979A (zh) * 2013-05-03 2016-02-17 西莱克塔生物科技公司 用于增强cd4+调节性t细胞的方法和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis";Ahlstrom-Emanuelsson et al.;《CLINICAL AND EXPERIMENTAL ALLERGY》;20040531;第34卷(第5期);全文 *

Also Published As

Publication number Publication date
US11458106B2 (en) 2022-10-04
ES2871537T3 (es) 2021-10-29
US20220370370A1 (en) 2022-11-24
US20170367988A1 (en) 2017-12-28
EP3454835B1 (en) 2021-03-31
JP2022058438A (ja) 2022-04-12
CN109152735A (zh) 2019-01-04
JP2019514979A (ja) 2019-06-06
WO2017194454A1 (en) 2017-11-16
JP7066632B2 (ja) 2022-05-13
EP3454835A1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
CN109152735B (zh) 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法
Kapadia et al. Spherical nucleic acid nanoparticles: therapeutic potential
Ferrer et al. Structure-dependent biodistribution of liposomal spherical nucleic acids
Pham Nanotherapeutic approaches for the treatment of rheumatoid arthritis
JP4885715B2 (ja) イリノテカン製剤
JP2002508765A (ja) リポソーム被包ポリヌクレオチド組成物および方法
CN112543629A (zh) 外泌体胞外囊泡及其使用方法
Lee et al. Suppression of human arthritis synovial fibroblasts inflammation using dexamethasone-carbon nanotubes via increasing caveolin-dependent endocytosis and recovering mitochondrial membrane potential
US20100203112A1 (en) Composition of cationic phospholipid nanoparticles for effective delivery of nucleic acids
WO2008052766A2 (en) Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
EP2422776A1 (en) Polyarginine nanocapsules
Ji et al. Synaptic vesicle-inspired nanoparticles with spatiotemporally controlled release ability as a “nanoguard” for synergistic treatment of synucleinopathies
Qin et al. Nanotechnology-based drug delivery systems for treating acute kidney injury
Marcato Pharmacokinetics and pharmacodynamics of nanomaterials
JP2023513302A (ja) 治療的に活性な作用物質を内皮へと送達するための脂質組成物およびその使用
CN119405823B (zh) 一种基于g四链体rna的蛋白降解靶向嵌合体及其制备方法与应用
CN1947702A (zh) 脂质载体及其制造方法
EP4251598A2 (en) Long-acting and long-circulating delivery vehicles
US20040077888A1 (en) Polyamine-mediated transfection
KR101916941B1 (ko) 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법
CN114642734B (zh) 药物及siRNA共递送纳米复合物及其制备方法与应用
Song et al. Microenvironments‐Targeted Nanomaterials for Atherosclerosis Therapy
Akbar et al. Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy
CN110638760A (zh) 一种cxcr4修饰的蛇床子素长循环脂质体、制备方法以及其应用
WO2025217087A1 (en) Lipid nanoparticles for intracellular delivery of proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant